Skip to main content
Premium Trial:

Request an Annual Quote

Becton Dickinson's Q4 Revenues Rise 11 Percent

NEW YORK (GenomeWeb News) – Becton Dickinson today reported fourth-quarter revenue growth of around 11 percent, with double-digit growth coming from all three of its operating segments.
 
The Franklin Lakes, NJ-based firm brought in total revenues of $1.83 billion for the three-month period ended Sept. 30, up from $1.65 billion in the comparable period of 2007. Sales for BD Medical rose around 10 percent year over year to $953.1 million, while sales for BD Diagnostics increased 11 percent to $553.1 million from $497.9 million, and sales for BD Biosciences rose 16 percent to $329.5 million from $284.9 million.
 
Within BD Biosciences, sales for its cell analysis products rose 16 percent to $98.9 million from $85.1 million, and sales for its discovery labware products fell 6 percent to $37.9 million from $40.2 million.
 
BD’s net income for the quarter increased roughly 9 percent to $282.2 million, or $1.12 per share, from $259.8 million, or $1.03 per share.
 
Its R&D spending in the quarter rose 8 percent to $108.6 million from $100.4 million year over year, and its SG&A costs increased roughly 9 percent to $437.2 million from $399.5 million.
 
For full-year 2008, BD reported a 12 percent increase in revenues to $7.16 billion from $6.36 billion. Sales for BD Medical Products rose 11 percent to $3.8 billion from $3.4 billion, while sales for BD Diagnostics increased 13 percent to $2.2 billion from $1.9 billion, and sales for BD Biosciences climbed around 16 percent to $1.2 billion from $1 billion.
 
The firm’s FY2008 profit was $1.13 billion, or $4.46 per share, compared to $890 million, or $3.49 per share, for fiscal 2007. Its SG&A expenses increased 7 percent to $1.7 billion from $1.6 billion, and its R&D spending rose 10 percent to $396.2 million from $360 million.
 
BD did not provide its cash position as of Sept. 30.
 
It said that it expects fiscal 2009 revenues to increase around 1 percent to 2 percent over 2008, with unfavorable foreign currency translation of an estimated 5 percent to 6 percent.
 

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.